{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:02:55Z","timestamp":1780718575735,"version":"3.54.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.6053-25","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:08:34Z","timestamp":1760566114000},"page":"1524-1528","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune Hemolytic Anemia Occurring One Year Before Acute Leukemic Manifestation of Lymphoma with a Chronic Lymphocytic Leukemia Immunophenotype"],"prefix":"10.2169","volume":"65","author":[{"given":"Shohei","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuko","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Diagnostic Pathology Department, Kochi Medical School Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Asagiri","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, Kochi Medical School Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Umebara","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Department, Kochi Medical School Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36: 1720-1748, 2022.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95: 2786-2792, 2000.","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131: 2745-2760, 2018.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 116: 4771-4776, 2010.","DOI":"10.1182\/blood-2010-05-286500"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 139: 791-798, 2007.","DOI":"10.1111\/j.1365-2141.2007.06859.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica 93: 151-152, 2008.","DOI":"10.3324\/haematol.11822"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Michel M, Crickx E, Fattizzo B, Barcellini W. Autoimmune haemolytic anaemias. Nat Rev Dis Primers 10: 82, 2024.","DOI":"10.1038\/s41572-024-00566-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Menter T, Trivedi P, Ahmad R, et al. Diagnostic utility of lymphoid enhancer binding factor 1 immunohistochemistry in small B-cell lymphomas. Am J Clin Pathol 147: 292-300, 2017.","DOI":"10.1093\/ajcp\/aqw208"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nikitin E, Kislova M, Morozov D, et al. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias. Leukemia 37: 1464-1473, 2023.","DOI":"10.1038\/s41375-023-01891-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Autore F, Pasquale R, Innocenti I, Fresa A, Sora' F, Laurenti L. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review. Cancers (Basel) 13: 5804, 2021.","DOI":"10.3390\/cancers13225804"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Galletti J, Ca\u00f1ones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol 181: 3674-3683, 2008.","DOI":"10.4049\/jimmunol.181.5.3674"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Taghiloo S, Asgarian-Omran H. Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: an update review. Eur J Haematol 113: 4-15, 2024.","DOI":"10.1111\/ejh.14224"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Han W, Jackson DA, Matissek SJ, et al. Novel molecular mechanism of regulation of CD40 ligand by the transcription factor GLI2. J Immunol 198: 4481-4489, 2017.","DOI":"10.4049\/jimmunol.1601490"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Peters FS, Strefford JC, Eldering E, Kater AP. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica 106: 1234-1243, 2021.","DOI":"10.3324\/haematol.2020.267914"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 34: 2012-2024, 2020.","DOI":"10.1038\/s41375-020-0873-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Svanberg Teglgaard R, Marquart HV, Hartling HJ, et al. Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials. Clin Cancer Res 30: 1959-1971, 2024.","DOI":"10.1158\/1078-0432.CCR-23-2522"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6053-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:29:52Z","timestamp":1780716592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6053-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6053-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"6053-25"}}